Purple Biotech (PPBT) files Form 6-K on new presentation

Purple Biotech Ltd. filed a Form 6-K to notify investors that it has released an updated corporate presentation titled “Purple Biotech Corporate Presentation November 2025.” The presentation is furnished as Exhibit 99.1.

Rhea-AI Filing Summary

Purple Biotech Ltd. filed a Form 6-K to notify investors that it has released an updated corporate presentation titled “Purple Biotech Corporate Presentation November 2025.” The presentation is furnished as Exhibit 99.1. This type of filing is mainly informational, giving the market updated background on the company and its activities rather than announcing a specific transaction or new financial results.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Purple Biotech Ltd. (PPBT) report in this Form 6-K?

Purple Biotech Ltd. reported that it issued an updated corporate presentation titled “Purple Biotech Corporate Presentation November 2025”, furnished as Exhibit 99.1.

What is Exhibit 99.1 in Purple Biotech’s November 2025 Form 6-K?

Exhibit 99.1 is the Purple Biotech Corporate Presentation November 2025, which provides updated company information in presentation format.

Does this PPBT Form 6-K announce any major transaction or deal?

No major transaction or deal is described; the Form 6-K reports the issuance of an updated corporate presentation.

Are financial results included in this Purple Biotech Form 6-K?

The Form 6-K states that Purple Biotech issued an updated corporate presentation; it does not describe specific financial results.

Who signed the November 2025 Form 6-K for Purple Biotech?

The Form 6-K was signed on behalf of Purple Biotech Ltd. by Gil Efron, Chief Executive Officer, dated November 19, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/19/2025 - 05:07 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of November 2025

Commission File Number: 001-37643

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Purple Biotech

On November 19, 2025, Purple Biotech Ltd. (the “Company” or the “Registrant”) issued an updated Company presentation, “Purple Biotech Corporate Presentation November 2025”, which is attached hereto as Exhibit 99.1.

Exhibit
99.1		Purple Biotech Corporate Presentation November 2025

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

November 19, 2025	PURPLE BIOTECH LTD.
	By:	/s/ Gil Efron
		Gil Efron
		Chief Executive Officer

2